ArticleGastroenterology research and practice2025
Compound Sophorae Decoction Alleviates Ferroptosis in Colitis Rats via Activating Keap1/Nrf2/GPX4 Signaling Pathway.
Article in Gastroenterology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mechanistic Networks, Cellular Specificity, and Therapeutic Opportunities of Ferroptosis in Ulcerative Colitis.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Article
- Compound Sophorae Decoction Alleviates Ferroptosis in Colitis Rats via Activating Keap1/Nrf2/GPX4 Signaling Pathway.Gastroenterology research and practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Compound sophorae decoction (CSD) has been extensively applied in clinic for the treatment of ulcerative colitis (UC). However, the effect and precise therapeutic mechanism have not been fully clarified. In this study, we systematically explored the protective efficacy and the underlying molecular mechanisms of CSD against UC. Methods: The main constituents of CSD were analyzed by HPLC-MS/MS and TLC. H Results: Then, 10 main active components were identified in CSD. CSD significantly attenuated DSS-induced intestinal injury and inflammation. Moreover, CSD notably decreased oxidative stress and lipid peroxidation. Mechanistically, CSD suppressed ferroptosis in DSS-induced UC and upregulated GPX4 and SLC7A11 expression through the activation of Nrf2 signaling in DSS-induced rats. Conclusions: Collectively, this study demonstrated that CSD ameliorates ferroptosis in DSS-induced UC rats, with its protective effects attributed to the activation of the Keap1/Nrf2/GPX4 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.